Literature DB >> 27532775

Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation.

Volker M Lauschke1, Sabine U Vorrink2, Sabrina M L Moro2, Fatemah Rezayee2, Åsa Nordling2, Delilah F G Hendriks2, Catherine C Bell2, Rowena Sison-Young3, B Kevin Park3, Christopher E Goldring3, Ewa Ellis4, Inger Johansson2, Souren Mkrtchian2, Tommy B Andersson2,5, Magnus Ingelman-Sundberg2.   

Abstract

Hepatocytes are dynamic cells that, upon injury, can alternate between nondividing differentiated and dedifferentiated proliferating states in vivo. However, in two-dimensional cultures, primary human hepatocytes (PHHs) rapidly dedifferentiate, resulting in loss of hepatic functions that significantly limits their usefulness as an in vitro model of liver biology, liver diseases, as well as drug metabolism and toxicity. Thus, understanding the underlying mechanisms and stalling of the dedifferentiation process would be highly beneficial to establish more-accurate and relevant long-term in vitro hepatocyte models. Here, we present comprehensive analyses of whole proteome and transcriptome dynamics during the initiation of dedifferentiation during the first 24 hours of culture. We report that early major rearrangements of the noncoding transcriptome, hallmarked by increased expression of small nucleolar RNAs, long noncoding RNAs, microRNAs (miRNAs), and ribosomal genes, precede most changes in coding genes during dedifferentiation of PHHs, and we speculated that these modulations could drive the hepatic dedifferentiation process. To functionally test this hypothesis, we globally inhibited the miRNA machinery using two established chemically distinct compounds, acriflavine and poly-l-lysine. These inhibition experiments resulted in a significantly impaired miRNA response and, most important, in a pronounced reduction in the down-regulation of hepatic genes with importance for liver function. Thus, we provide strong evidence for the importance of noncoding RNAs, in particular, miRNAs, in hepatic dedifferentiation, which can aid the development of more-efficient differentiation protocols for stem-cell-derived hepatocytes and broaden our understanding of the dynamic properties of hepatocytes with respect to liver regeneration.
CONCLUSION: miRNAs are important drivers of hepatic dedifferentiation, and our results provide valuable information regarding the mechanisms behind liver regeneration and possibilities to inhibit dedifferentiation in vitro. (Hepatology 2016;64:1743-1756).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27532775     DOI: 10.1002/hep.28780

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Hepatocyte spheroids as an alternative to single cells for transplantation after ex vivo gene therapy in mice and pig models.

Authors:  Clara T Nicolas; Raymond D Hickey; Kari L Allen; Zeji Du; Rebekah M Guthman; Robert A Kaiser; Bruce Amiot; Aditya Bansal; Mukesh K Pandey; Lukkana Suksanpaisan; Timothy R DeGrado; Scott L Nyberg; Joseph B Lillegard
Journal:  Surgery       Date:  2018-06-06       Impact factor: 3.982

2.  Expression dynamics of pregnane X receptor-controlled genes in 3D primary human hepatocyte spheroids.

Authors:  Tomas Smutny; Veronika Bernhauerova; Lucie Smutna; Jurjen Duintjer Tebbens; Petr Pavek
Journal:  Arch Toxicol       Date:  2021-10-23       Impact factor: 5.153

3.  Mapping the miRNA-mRNA Interactome in Human Hepatocytes and Identification of Functional mirSNPs in Pharmacogenes.

Authors:  Nicholas R Powell; Harrison Zhao; Joseph Ipe; Yunlong Liu; Todd C Skaar
Journal:  Clin Pharmacol Ther       Date:  2021-08-13       Impact factor: 6.903

4.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

5.  From in vivo to in vitro: Major metabolic alterations take place in hepatocytes during and following isolation.

Authors:  Shamir Cassim; Valérie-Ann Raymond; Pascal Lapierre; Marc Bilodeau
Journal:  PLoS One       Date:  2017-12-28       Impact factor: 3.240

6.  Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics.

Authors:  Sabine U Vorrink; Shahid Ullah; Staffan Schmidt; Jatin Nandania; Vidya Velagapudi; Olof Beck; Magnus Ingelman-Sundberg; Volker M Lauschke
Journal:  FASEB J       Date:  2017-03-06       Impact factor: 5.191

7.  The hepatocyte proteome in organotypic rat liver models and the influence of the local microenvironment.

Authors:  Lucas T Vu; Sophia M Orbach; W Keith Ray; Margaret E Cassin; Padmavathy Rajagopalan; Richard F Helm
Journal:  Proteome Sci       Date:  2017-06-20       Impact factor: 2.480

8.  Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury.

Authors:  Catherine C Bell; Volker M Lauschke; Sabine U Vorrink; Henrik Palmgren; Rodger Duffin; Tommy B Andersson; Magnus Ingelman-Sundberg
Journal:  Drug Metab Dispos       Date:  2017-01-30       Impact factor: 3.922

9.  Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study.

Authors:  Catherine C Bell; Anita C A Dankers; Volker M Lauschke; Rowena Sison-Young; Roz Jenkins; Cliff Rowe; Chris E Goldring; Kevin Park; Sophie L Regan; Tracy Walker; Chris Schofield; Audrey Baze; Alison J Foster; Dominic P Williams; Amy W M van de Ven; Frank Jacobs; Jos van Houdt; Tuula Lähteenmäki; Jan Snoeys; Satu Juhila; Lysiane Richert; Magnus Ingelman-Sundberg
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

Review 10.  The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity.

Authors:  Volker M Lauschke; Magnus Ingelman-Sundberg
Journal:  Int J Mol Sci       Date:  2016-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.